GlassScriptPhysician profile
Sandra S Catlin
NPI 1447205760
$3,429.92
in general payments reported to CMS, 2019-2025
29 companies · $847 in 2025
The $847 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $764 · 2023: $651 · 2024: $716 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.51 | 2021-2025 | |
| Amgen INC. | $739.27 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $248.35 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $224.25 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $127.01 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $119.04 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $103.06 | 2022-2024 | |
| Vanda Pharmaceuticals INC. | $91.87 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.92 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $78.09 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.24 | 2022 | |
| Corcept Therapeutics | $65.79 | 2024 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $63.40 | 2022 | |
| Axsome Therapeutics, INC. | $56.71 | 2022-2025 | Auvelity |
| Mylan Specialty L.P. | $41.37 | 2021-2024 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.99 | 2021-2024 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $27.85 | 2025 | Uzedy |
| Acadia Pharmaceuticals INC | $27.61 | 2021-2025 | Daybue |
| Boston Scientific Corporation | $22.03 | 2022 | |
| Nevro Corp. | $17.08 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.83 | 2024 | |
| Medtronic, INC. | $16.76 | 2025 | Intellis Adaptivestim |
| Sanofi Pasteur INC. | $16.76 | 2023 | |
| Biogen, INC. | $16.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.94 | 2023 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $15.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.13 | 2021 | |
| Hologic Sales and Service, LLC | $13.53 | 2024 | Novasure |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Catlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.